Keros Therapeutics, Inc.

Keros Therapeutics, Inc. has updated its corporate presentation, which is now available on its website and attached as an exhibit to its Form 8-K filing. The presentation outlines the company's strategy to develop differentiated product candidates targeting the TGF-β superfamily signaling pathway for a range of diseases. Key product candidates discussed include Rinvatercept (KER-065) for neuromuscular disorders like DMD and ALS, and Elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis, developed in partnership with Takeda. The presentation also introduces KER-206, a nonclinical asset aimed at bone disorders.

Keros Therapeutics reported a net loss of $28.71 million for the second quarter of 2026, with total revenue at $0, a significant decrease from the prior year's period which included license revenue. For the first six months of 2026, the company posted a net loss of $52.42 million, contrasting with a net income of $117.76 million in the same period of 2025. Cash and cash equivalents stood at $257.61 million as of June 30, 2026, reflecting ongoing operational expenses for its clinical-stage pipeline.

Keros Therapeutics reported a net loss of $28.7 million for Q2 2026, a decrease from $30.7 million in Q2 2025. Research and development expenses significantly decreased by $21.2 million to $22.3 million, primarily due to the transition of elritercept-related expenses to Takeda and a 2025 corporate restructuring. General and administrative expenses also fell to $8.6 million. The company initiated a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy and expects initial data in H1 2027, while maintaining a cash position of $257.6 million, sufficient to fund operations into H1 2028.

Keros Therapeutics reported a net loss of $28.7 million for the second quarter of 2026, an improvement from a $30.7 million net loss in the prior year. The company also announced the initiation of a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy patients, with initial data anticipated in the first half of 2027. Significant decreases in R&D and G&A expenses were noted due to the transition of elritercept-related R&D to Takeda and a 2025 corporate restructuring. Keros expects its $257.6 million in cash and cash equivalents to fund operations into the first half of 2028.

Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from its partner Takeda Pharmaceuticals U.S.A., Inc. This payment follows the dosing of the first patient in the ELRiSE MDS clinical trial, a Phase 3 study evaluating elritercept for the treatment of anemia due to myelodysplastic syndromes. Keros plans to distribute 25% of the net cash proceeds from this milestone to its stockholders. The company previously received a $200 million upfront payment in February 2025 and is eligible for over $1.1 billion in potential future milestones under the license agreement.

Keros Therapeutics announced the resignation of Chief Financial Officer Keith Regnante, effective August 3, 2026, as he pursues other opportunities. Annita Tanini, the company's Corporate Controller and Vice President, Finance, has been appointed interim principal financial officer and principal accounting officer, effective August 4, 2026. Ms. Tanini will receive an annual base salary of $302,300 and is eligible for an annual cash bonus with a target of 30% of her base salary. The company has initiated a search for a permanent CFO.

Keros Therapeutics, Inc. announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026. The company highlighted Dr. Prener's extensive experience in clinical development and executive leadership, which is expected to be invaluable in advancing Keros' pipeline and corporate strategy. Dr. Prener expressed enthusiasm for joining Keros, citing its differentiated scientific approach and commitment to addressing unmet patient needs.

Keros Therapeutics, Inc. announced that its President and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time, with a live audio webcast and an archived replay available for investors. Keros is a clinical-stage biopharmaceutical company developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins.

Keros Therapeutics reported a net loss of $(23.7) million for Q1 2026, a significant decline from a net income of $148.5 million in Q1 2025. Total revenue plummeted to $367 thousand from $211.2 million year-over-year, primarily due to the absence of large license revenue recognized in the prior year. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, down from $287.4 million at the end of 2025. Management believes existing cash will allow operations for at least the next 12 months, but continued viability depends on raising additional capital.

Keros Therapeutics reported a net loss of $23.7 million for Q1 2026, a significant decrease from a net income of $148.5 million in Q1 2025, primarily due to lower revenue from a Takeda license agreement and reduced R&D expenses. The company's partner, Takeda, plans to advance elritercept into a Phase 3 clinical trial for anemia in myelofibrosis. Keros maintains a strong cash position of $281.5 million, expected to fund operations into the first half of 2028.